Literature DB >> 23748128

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

Deborah Cohen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23748128     DOI： 10.1136/bmj.f3680

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.

Authors:  Martin Haluzík; Miloš Mráz; Štěpán Svačina
Journal:  Drug Saf       Date:  2014-12       Impact factor: 5.606

2.  Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Authors:  Jens Juul Holst
Journal:  Diabetologia       Date:  2013-07-03       Impact factor: 10.122

3.  Incretin-based therapies: facing the realities of benefits versus side effects.

Authors:  Harold E Lebovitz
Journal:  Diabetes Technol Ther       Date:  2013-10-10       Impact factor: 6.118

4.  Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

Authors:  S Bonner-Weir; P A In't Veld; G C Weir
Journal:  Diabetes Obes Metab       Date:  2014-01-29       Impact factor: 6.577

Review 5.  Systematic reviews to ascertain the safety of diabetes medications.

Authors:  Michael R Gionfriddo; Oscar L Morey-Vargas; Juan P Brito; Aaron L Leppin; M Hassan Murad; Victor M Montori
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

6.  In pursuit of normoglycaemia: the overtreatment of type 2 diabetes in general practice.

Authors:  Jonathan D Sleath
Journal:  Br J Gen Pract       Date:  2015-07       Impact factor: 5.386

7.  Glucagonlike peptide 1 analogs in diabetes care.

Authors:  Adrienne J Lindblad; Scott Garrison; G Michael Allan
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

8.  Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!

Authors:  Michael A Nauck; Juris J Meier
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

Review 9.  Pharmacotherapy for obesity: novel agents and paradigms.

Authors:  Sean Manning; Andrea Pucci; Nicholas Finer
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 10.  Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

Authors:  G R Kolar; S M Grote; G L C Yosten
Journal:  J Intern Med       Date:  2016-06-16       Impact factor: 8.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.